CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Troncy, E.
Right arrow Articles by Blaise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Troncy, E.
Right arrow Articles by Blaise, G.

Canadian Journal of Anesthesia, Vol 44, 973-988, Copyright © 1997 by Canadian Anesthesiologists' Society

ARTICLES

Inhaled nitric oxide: clinical applications, indications, and toxicology

E Troncy, M Francoeur and G Blaise
Department of Anaesthesia, Centre Hospitalier de l'Universite de Montreal-Pavillon Notre-Dame, Quebec, Canada.

PURPOSE: Although the analogy of nitric oxide (NO) to Endothelium-derived Relaxing Factor remains controversial, medical use of exogenous NO gas by inhalation has grown exponentially. This review presents the mechanisms of action of inhaled NO in pulmonary hypertension, hypoxaemia, inflammation and oedema, as well as its therapeutic and diagnostic indications with emphasis on acute respiratory distress syndrome (ARDS) and toxicology. SOURCE: Two medical databases (Current Contents, Medline) were searched for citations containing the above-mentioned key words to December 1996. Moreover, many presentations in congresses such as 4th International Meeting of Biology of Nitric Oxide, 52nd and 53rd Annual Meeting of Canadian Anaesthetists' Society or 10th Annual Meeting of European Association of Cardiothoracic Anaesthesiologists were used. PRINCIPAL FINDINGS: Inhaled NO is now recognized as an invaluable tool in neonatal and paediatric critical care, and for heart/lung surgery. Other clinical applications in adults, such as chronic obstructive pulmonary disease and ARDS, require a cautious approach. The inhaled NO therapy is fairly inexpensive, but it would seem that it is not indicated for everybody with regards to the paradigm of its efficiency and potential toxicity. The recent discovery of its anti-inflammatory and extrapulmonary effects open new horizons for future applications. CONCLUSION: Clinical use of inhaled NO was mostly reported in case series, properly designed clinical trials must now be performed to establish its real therapeutic role. These trials would permit adequate selection of the cardiopulmonary disorders, and subsequently the patients that would maximally benefit from inhaled NO therapy.


This article has been cited by other articles:


Home page
 J. Epidemiol. Community HealthHome page
J.-B. Ruidavets, S. Cassadou, M. Cournot, V. Bataille, M. Meybeck, and J. Ferrieres
Increased resting heart rate with pollutants in a population based study
J. Epidemiol. Community Health, August 1, 2005; 59(8): 685 - 693.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond
Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs]
Can J Anesth, October 1, 2001; 48(9): 924 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. Joffs, C. A. Walker, J. W. Hendrick, D. J. Fary, D. K. Almany, J. N. Davis, A. T. Goldberg, F. A. Crawford Jr, and F. G. Spinale
Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 365 - 370.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath
Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520.
[Abstract] [Full Text]

Home page
 Canadian J. AnesthesiaHome page
D. Campbell, M. Steinmann, and L. Porayko
Nitric oxide and high frequency jet ventilation in a patient with bilateral bronchopleural fistulae and ARDS
Can J Anesth, January 1, 2000; 47(1): 53 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. Hanasato, M. Oka, M. Muramatsu, M. Nishino, H. Adachi, and Y. Fukuchi
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats
Am J Physiol Lung Cell Mol Physiol, August 1, 1999; 277(2): L225 - L232.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. M. Hart
Nitric Oxide in Adult Lung Disease
Chest, May 1, 1999; 115(5): 1407 - 1417.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Canadian Anesthesiologists' Society.